KBC Group’s CG Oncology CGON Stock Holding History

KBC Group’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$82K	Hold	1,153	–	–	﹤0.01%	1515
2026 Q1	$78K	Buy	+1,153	New	+$65.3K	﹤0.01%	1463

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KBC Group's CGON Position: Q2 2026 in Review

KBC Group held its CG Oncology (CGON) position steady in Q2 2026 at 1,153 shares worth $82K. The position accounts for ﹤0.01% of the portfolio, ranked #1515.

KBC Group first reported a position in CGON in Q1 2026 and has held it in 2 quarters since. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

KBC Group held 1,153 shares of CG Oncology worth $82K as of Q2 2026.
KBC Group left its CG Oncology share count unchanged in Q2 2026.
CG Oncology made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1515 holding.
KBC Group first reported a position in CG Oncology in Q1 2026 and has held it in 2 quarters since.
228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.